NCT01936090View on ClinicalTrials.gov

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 2, 2016

Study Completion Date

February 16, 2018

Conditions
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
DRUG

Bortezomib

Given IV

RADIATION

Total-Body Irradiation

Undergo TBI

DRUG

Melphalan

Given IV

PROCEDURE

Autologous Bone Marrow Transplantation

Undergo autologous bone marrow transplant

PROCEDURE

Autologous Hematopoietic Stem Cell Transplantation

Undergo autologous peripheral blood stem cell transplant

PROCEDURE

Peripheral Blood Stem Cell Transplantation

Undergo autologous peripheral blood stem cell transplant

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01936090 - Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter